Cordis, GenVec Collaborate On Cardiac Drug Delivery Trial To Begin Mid-2004
This article was originally published in The Gray Sheet
Executive Summary
Intravascular delivery of GenVec's Biobypass angiogenic drug via Johnson & Johnson/Cordis' Myostar catheter will be evaluated in a 125-patient randomized trial featuring a "sham" placebo control
You may also be interested in...
MIT Spin-Off Evaluates Vascular Drug Delivery With $500,000 In VC Funds
Pervasis Therapeutics will rely in part on seed money from two Boston venture capital firms to help commercialize a vascular drug delivery device that would promote tissue healing
MIT Spin-Off Evaluates Vascular Drug Delivery With $500,000 In VC Funds
Pervasis Therapeutics will rely in part on seed money from two Boston venture capital firms to help commercialize a vascular drug delivery device that would promote tissue healing
Cardiac Stem Cell Alliances Include Large Firms; MacroPore “Grows” It Alone
MacroPore Biosurgery insists it will pursue solo development of stem cell therapy for myocardial infarction, even though competitors are increasingly aligning with large cardiovascular device firms